Aflibercept

First results to be presented in two ASCO oral presentations Data in both combinations demonstrate high response rates TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with two different proteasome inhibitors (PI) – carfilzomib or bortezomib – in patients with relapsed/refractory (R/R) multiple myeloma (MM). The trial included patients who had progressed after at least two lines of therapy and were either double-class refractory (immunomodulatory drug [IMiD] and PI) or triple-class exposed (IMiD, PI and anti-CD38 monoclonal antibody). The data will be featured in two oral presentations at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting on Monday, June 2 at 8:00 AM CDT. “In clinical trials, treatment with linvoseltamab monotherapy in later-line settings generated impressive response rates, warranting investigation in earlier lines as well as in combination with other cancer therapies,” said Salomon Manier, M.D., Ph.D., Professor of Hematology at Lille University Hospital in France. “While early, these compelling results for linvoseltamab combination therapy demonstrated high rates of clinical activity, even amongst those with previous exposure to the proteasome inhibitors evaluated in the cohorts. We look forward to seeing these results mature to see if these benefits can be maintained.” Linvoseltamab combined with carfilzomib showed strong responses in R/R MM All treated patients (n=23) had previous exposure to PIs and more than half (n=12) were refractory to at least one PI. Moreover, 48% had baseline soft tissue plasmacytomas, and 39% were over 75 years old, representing a patient population with high-risk features. Of the 21 patients evaluable for efficacy, 11 patients received linvoseltamab 100 mg, and five patients each received linvoseltamab 150 mg or 200 mg prior to initiation of carfilzomib. With a median follow-up of 15 months, efficacy results across all dose levels showed a 90% objective response rate (ORR; 19 of 21 patients), with 76% (16 of 21 patients) achieving a complete response (CR). At 12 months, the estimated probability of maintaining a response was 87% (n=19; 95% confidence interval [CI]: 56% to 97%) and being progression-free was 83% (n=21; 95% CI: 55% to 94%). A registrational, randomized Phase 3 trial investigating this combination against standard-of-care in the same setting is planned. Among the 23 patients evaluable for safety, the most common treatment emergent adverse events (TEAEs; >50%) of any grade and Grade ≥3 were neutropenia (65% and 56.5%), cytokine release syndrome (CRS; 61% and 0%), diarrhea (52% and 4%) and thrombocytopenia (52% and 30%). Infections occurred in 91% of patients (Grade ≥3: 43.5%, including one fatality). Serious adverse events (SAEs) occurred in 83% of patients. One dose-limiting toxicity (DLT) of Grade 4 thrombocytopenia during tumor lysis syndrome was observed in the 100 mg dose level, and one Grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS) was observed in the 150 mg dose level. Additional linvoseltamab combination with bortezomib showed promising clinical activity in R/R MM Among enrolled patients (n=24), 6 received linvoseltamab at 100 mg and 18 at 200 mg before initiating bortezomib. More than half were refractory to PIs, including 58% to carfilzomib and 13% to bortezomib. Of the 20 patients evaluable for efficacy and with a median duration of follow-up of 9 months, results across dose levels showed an 85% ORR (17 of 20 patients), with 50% (10 of 20 patients) achieving a CR. The most common TEAEs (>50%) of any grade and Grade ≥3 were CRS (58% and 0%), neutropenia (54% and 50%) and thrombocytopenia (54% and 37.5%). Four patients experienced ICANS (one Grade 1 and three Grade 2). Infections occurred in 75% of patients (Grade ≥3: 38%). SAEs occurred in 83% of patients. Two patients died due to adverse events: one due to pneumonia deemed related to treatment and occurring prior to initiation of bortezomib, and another due to COVID-19 deemed unrelated to treatment. One DLT of Grade 3 cytomegalovirus reactivation was observed in the 200 mg dose level. The uses of linvoseltamab in combination with either carfilzomib or bortezomib in patients with R/R MM are investigational and have not been approved by any regulatory authority. Linvoseltamab is approved in the European Union as Lynozyfic™ for adults to treat R/R MM that has progressed after at least three prior therapies (including a PI, an IMiD and an anti-CD38 monoclonal antibody) and that has demonstrated progression on the last therapy. For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu. In the U.S., the FDA accepted for review the Biologics License Application for linvoseltamab in adults with R/R MM with a target action date of July 10, 2025. About Multiple Myeloma As the second most common blood cancer, there are over 187,000 new cases of MM diagnosed globally every year, with more than 36,000 diagnosed and 12,000 deaths anticipated in the U.S. in 2025. In the U.S., there are approximately 8,000 people who have MM that has progressed after three lines of therapy. The disease is characterized by the proliferation of cancerous plasma cells (MM cells) that crowd out healthy blood cells in the bone marrow, infiltrate other tissues and cause potentially life-threatening organ injury. Despite treatment advances, MM is not curable and while current treatments are able to slow progression of the cancer, most patients will ultimately experience cancer progression and require additional therapies. About LINKER-MM2 LINKER-MM2 is a Phase 1b, open-label clinical trial evaluating linvoseltamab in combination with other cancer treatments in patients with R/R MM. Combination treatments include standard-of-care and novel therapies such as IMiD, PIs, anti-CD38 antibodies, checkpoint inhibitors, and a gamma secretase inhibitor. The primary endpoints are incidence of DLTs (dose-finding portion only) and incidence and severity of TEAEs. Secondary endpoints include ORR, DoR and progression-free survival. In the carfilzomib cohort, linvoseltamab is administered first with an initial step-up dosing regimen followed by at least two full doses (100, 150 or 200 mg) before initiation of carfilzomib (56 mg/m²). In the bortezomib cohort, the same initial step-up process is followed but linvoseltamab is administered with at least one full dose (100 or 200 mg) before initiation of bortezomib (1.3 mg/m²). About the Linvoseltamab Clinical Development Program Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing. Linvoseltamab is being investigated in a broad clinical development program exploring its use as a monotherapy as well as in combination regimens across different lines of therapy in MM, including earlier lines of treatment, as well as plasma cell precursor disorders. In addition to LINKER-MM2, trials include: LINKER-MM1: Phase 1/2 dose-escalation and dose-expansion trial evaluating the safety, tolerability, dose-limiting toxicities and anti-tumor activity of linvoseltamab monotherapy in R/R MM LINKER-MM3: Phase 3 confirmatory trial evaluating linvoseltamab monotherapy compared to the combination of elotuzumab, pomalidomide and dexamethasone in R/R MM Phase 1 trial evaluating linvoseltamab in combination with a Regeneron CD38xCD28 costimulatory bispecific in R/R MM LINKER-MM4: Phase 1/2 trial evaluating linvoseltamab monotherapy in newly diagnosed MM LINKER-SMM1: Phase 2 trial evaluating linvoseltamab monotherapy in high-risk smoldering MM LINKER-MGUS1: Phase 2 dose-ranging trial evaluating linvoseltamab monotherapy in high-risk monoclonal gammopathy of unknown significance and non-high-risk SMM LINKER-AL2: Phase 1/2 trial evaluating linvoseltamab monotherapy in R/R systemic light chain amyloidosis For more information on Regeneron’s clinical trials in blood cancer, visit the clinical trials website, or contact via clinicaltrials@regeneron.com or 844-734-6643. About Regeneron in Hematology At Regeneron, we’re applying more than three decades of biology expertise with our proprietary VelociSuite® technologies to develop medicines for patients with diverse blood cancers and rare blood disorders. Our blood cancer research is focused on bispecific antibodies that are being investigated both as monotherapies and in various combinations and emerging therapeutic modalities. Together, they provide us with unique combinatorial flexibility to develop customized and potentially synergistic cancer treatments. Our research and collaborations to develop potential treatments for rare blood disorders include explorations in antibody medicine, gene editing and gene-knockout technologies, and investigational RNA-approaches focused on depleting abnormal proteins or blocking disease-causing cellular signaling. About Regeneron's VelocImmune® Technology Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz® (pozelimab-bbfg). In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024. About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X. Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation linvoseltamab in combination with carfilzomib or bortezomib in patients with relapsed/refractory (“R/R”) multiple myeloma (“MM”); the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, including linvoseltamab as a monotherapy (such as for the treatment of R/R MM in the United States based on the Biologics License Application referenced in this press release) and in combination with carfilzomib or bortezomib or other combination regimens discussed or referenced in this press release across different lines of therapy in MM and plasma cell precursor disorders; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates (such as linvoseltamab in combination with the above-referenced agents); the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates (such as linvoseltamab in combination with the above-referenced agents) in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates (including biosimilar versions of Regeneron’s Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable) to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024 and its Form 10-Q for the quarterly period ended March 31, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals). Contacts: Source: Regeneron Pharmaceuticals, Inc.

半年时间，市值蒸发近700亿美元，曾经的全球生物技术“天花板”公司再生元，2.56亿美元押注基因测序，是精明抄底，还是“病急乱投医”？撰文｜Eileen当Q1交出业绩“负战绩”与2.56亿美元收购基因测序“破产”公司同时发生，曾经的全球生物技术巨星——再生元再难掩陷入“中年危机”的焦虑。数字揭示出最为残酷的现实：再生元自2024年年中攀登至1330亿美元市值巅峰后，仅不到1年时间就暴跌近700亿美元。市值跳水的背后是产品青黄不接的困境：接连造出阿柏西普、度普利尤单抗两款超级重磅炸弹后，却7年未诞生新爆款。而阿柏西普看似38%的眼科超高市场份额，头顶却有罗氏重磅双抗和5款生物类似药如达摩克利斯之剑高悬；5款销售额最高产品却横跨4个治疗领域，被全球生物技术创业者们追捧的“开放式创新”副作用也暴露无遗。再生元如今的困境其实折射出同时代成长为Pharma的生物技术公司们的集体焦虑。当技术红利再难维持业绩神话，当安进、吉利德同样深陷增长泥潭，似乎到了Biotech先驱们回答如何穿越周期，进入“大药厂”的生存法则的时候了。再生元不再年轻2024年年中，再生元与赛诺菲合作的度普利尤单抗以超61亿欧元的H1销售额，叠加5项新适应证年内获批预期，不仅使得赛诺菲成为TOP10跨国药企中仅有的两家实现两位数增长的企业之一，再生元市值攀升至1330亿美元历史高点。但谁也没能想到，在此之后仅不到1年的时间里，再生元能经历市值登顶到跌至谷底。截止发稿日（5月20日），再生元股价仅为596.54美元/股，市值644.06亿美元，距离最高峰近乎腰斩。不仅如此，再生元还交出了2025年Q1“负战绩”，收入仅为30.29亿美元，创下2023年以来最差单季度表现。遥想当年，其成立之初就携带的创新基因让行业望尘莫及：“两位科学家+行业传奇经理人”的创始团队“三剑客”构建了科学研发与商业运营的黄金组合；综合技术平台VelociSuite、转基因小鼠平台、抗体平台等核心技术平台使公司成为全球平台型生物技术公司的代表；再生元所打造的开放式创新研发环境，再加上阿柏西普和度普利尤单抗两款重磅新药先后问世，都使其成为Biotech“天花板”，试问哪位生物医药创业者没高喊过一句对标再生元。再生元业绩也一路高歌猛进。阿柏西普和度普利尤单抗先后于2011年、2017年首次获批上市，再加上在全球率先推出新冠中和抗体，再生元在2021年业绩达到历史巅峰160多亿美元，增速也直逼90%，即使是“宇宙大药厂”辉瑞都难以企及。然而，巅峰之下暗藏隐忧。阿柏西普和度普利尤单抗之后，再生元至今都未推出第三款惊艳全球制药行业的重磅新品。打开再生元的2024年年报，阿柏西普（包括阿柏西普和阿柏西普8mg）和度普利尤单抗仍以95.45亿、141.48亿美元销售额形成断崖式领先，第三大产品PD-1抑制剂Libtayo虽突破10亿美元门槛，但其2018年上市至今的缓慢爬坡凸显产品梯队断层。用百亿级重磅大药验证了生物技术平台型公司的爆发力，以及开放式创新环境所带来的高效研发成功率，却也暴露出战略纵深不足的短板。正是因为过于开放与分散，再生元缺少了培养一款“大单品”的基因，也缺少如罗氏、礼来、诺和诺德等MNC构建产品矩阵的深耕策略。再生元销售额前五的产品横跨眼科、自免、肿瘤、降脂四大领域，新管线更分散于罕见病、抗凝血等赛道，难以形成治疗领域的协同效应。这一点在核心产品阿柏西普的“攻防战”中展现的淋漓尽致。作为第二代VEGF单抗，阿柏西普最初上市之时，成功蚕食了罗氏与诺华合作的VEGF单抗雷珠单抗的市场份额。但罗氏并未因此放弃眼科市场，转而再次开发出了新一代VEGF眼科药物——VEGFA/ANGPT2双抗法瑞西单抗（Vabysmo），并且在上市初期就拿下年龄相关黄斑变性（AMD）、糖尿病黄斑水肿（DME）和视网膜静脉阻塞（RVO）三大眼科核心适应证。市场份额更是被分析机构预计今年将从13.5%跃升至18%，直逼阿柏西普38%的市占率。再生元如今虽推出阿柏西普8mg“升级版”应战，但面对双抗技术优势与罗氏强大的商业化体系，收复失地困难重重。更严峻的是，美国FDA已批准5款阿柏西普生物类似药，中国市场亦有齐鲁制药等仿制品虎视眈眈。再生元与赛诺菲合作的度普利尤单抗的成功也印证了战略聚焦的重要性——赛诺菲将其置于“Play to Win”战略核心，举全司之力打造自免领域王者。反观再生元，开放式创新模式虽提升研发效率，却导致资源过度分散。最新管线中， Evkeeza瞄准的是降脂领域的罕见病，在研产品涉足抗凝血等新领域，这种广撒网策略在当下高度竞争的制药行业，其实已难复制当年“双雄并立”的辉煌。 推荐阅读 * AZ超罗氏，礼来追赛诺菲，诺华掉出前五，全球制药营收TOP10洗牌* 辉瑞杀进第一！恒瑞自研全球第二，百济、石药、中生、华东爆发！6823家药企研发盘点“中年危机”转型困局从Biotech走到Biopharma的再生元，作为平台型生物技术公司的进化之路，或许正需要从开放创新向战略聚焦的转型。再生元其实也并未回避自身困境，本次并购基因测序先驱23andMe公司就是再生元转型棋盘上的一子。再生元的基因治疗布局可追溯至2014年，通过构建全球最大基因测序项目，已累计完成近300万人基因组测序。创始人之一的George Yancopoulos更提出雄心勃勃的“全民测序”计划，目标覆盖全美人口。收购拥有1500万用户遗传数据库的23andMe，显然是再生元最快引入海量遗传数据的方式。当然，收购23andMe的另一层含义则暗示出再生元从抗体治疗扩展至基因治疗领域，寻找下一个超级重磅炸弹的野心。但它真的能行吗？或许还是个疑问。首先，目前的再生元在传统布局领域仍多点开花。在自免领域，再生元押注了一款IL-33新药itepekimab，同样锚定哮喘、慢性阻塞性肺病（COPD）和特应性皮炎等重磅适应证；在抗肿瘤领域，Odronextamab、Linvoseltamab两款双抗虽然遭遇FDA的拒绝，但并非出于疗效和安全性问题，未来也有望再造爆款。值得一提的是，2024年，再生元还进军了风投界，成立风险投资基金Regeneron Ventures，专注于有前景的生物制药、医疗保健和技术公司。抗体领域风生水起，再生元在基因治疗上也有野心，这种“既要又要”的管线布局，即使手握170多亿美元现金流，但其实难以消除投资者对其资源分散的担忧。另一方面，基因治疗赛道本身的复杂性更添变数。就连罗氏、辉瑞、武田等制药巨头都接连碰壁，另一家生物技术明星福泰制药甚至宣布将停止使用腺相关病毒（AAV）作为基因治疗载体的研究。前车之鉴揭示出基因治疗领域的高技术门槛与商业化风险，再生元收购23andMe即使只花了2.56亿美元，但相较其擅长的抗体药物开发，基因治疗却需要截然不同的技术积累与临床经验。更深层的挑战在于商业逻辑的转变。对于再生元来说，或许需要及时回答的并非是能否坚守住作为全球生物技术高地的创新基因，而是作为一家营收百亿美元的上市制药公司，“赚钱”才是硬道理。阿柏西普生物类似药围攻在即，度普利尤单抗的竞品们虎视眈眈，二级市场更关注的是：在明星产品专利到期前，再生元能否通过现有临床管线再造爆款？这种紧迫的时间窗口，也与基因治疗尚未被完整验证过的研发周期形成尖锐矛盾。或许这也是再生元重回千亿美元市值的关键一役。当然，再生元如今的困境也折射出同时代成长为Pharma的生物技术公司们的集体焦虑。曾经被全球生物技术创业者们追捧的安进、吉利德似乎都在21世纪的第二个十年不再年轻，同样面临创新基因仍在与增长曲线放缓的“中年危机”。 当单纯依靠技术创新已难维持增长神话，如何从技术驱动转向战略驱动，在聚焦领域构建产品矩阵而非分散押注，或是这类企业穿越周期必须解答的命题。他们的“中年危机”也将是那些将Pharma视为里程碑的Biotech公司，未来突破困局的参考经验。一审| 黄佳二审| 李芳晨三审| 李静芝精彩推荐大事件 | IPO | 融资&交易 | 财报季 | 新产品 | 研发日 | 里程碑 | 行业观察 | 政策解读 | 深度案例 | 大咖履新 | 集采&国谈 | 出海 | 高端访谈 | 技术&赛道 | E企谈 | 新药生命周期 | 市值 | 新药上市 | 商业价值 | 医疗器械 | IND | 周年庆大药企 | 竞争力20强 | 恒瑞 | 石药 | 中生制药 | 齐鲁 | 复星 | 科伦 | 翰森 | 华润 | 国药 | 云南白药 | 天士力 | 华东 | 上药创新药企 | 创新100强 | 百济 | 信达 | 君实 | 复宏汉霖 | 康方 | 和黄 | 荣昌 | 亚盛｜康宁杰瑞｜贝达｜微芯｜再鼎｜亚虹跨国药企｜ＭＮＣ卓越｜辉瑞｜AZ｜诺华｜罗氏｜BMS｜默克｜赛诺菲｜GSK｜武田｜礼来｜诺和诺德｜拜耳供应链｜赛默飞｜药明｜凯莱英｜泰格｜思拓凡｜康龙化成｜博腾｜晶泰｜龙沙｜三星启思会 | 声音·责任 | 创百汇 | E药经理人理事会 | 微解药直播 | 大国新药 | 营销硬观点 | 投资人去哪儿 | 分析师看赛道 | 药事每周谈 | 中国医药手册